Cala Health is founded from Stanford University to develop new treatments for movement disorders.
We’re building innovative therapies that profoundly impact people’s lives.
About Cala Health
At Cala Health, we’re working to free people from the burden of chronic disease. We began by developing Cala TAPS® therapy, the first non-invasive, clinically proven therapy for action hand tremor. Therapy is delivered through a wearable device to effectively reduce tremor in people with essential tremor and Parkinson’s disease. Cala TAPS® therapy is FDA-cleared and physician-prescribed. To date, our products have empowered thousands of people to get back to their lives with confidence and ease. Founded in 2014, Cala Health is headquartered in the San Francisco Bay Area and backed by leading investors in both healthcare and technology.
Stacy Enxing Seng
Chairwoman of the Board
James Lee
Board Director
Jordi Parramon
Board Director
Juan-Pablo Mas
Board Director
Mike Carusi
Board Director
John Kuelper
Board Director
Neil Tiwari
Board Director
Deanna Harshbarger
Chief Executive Officer
Kate Rosenbluth, PhD
President & Chief Innovation Officer
The story so far
Cala completes ET-03, a multi-center, randomized, controlled trial to assess the safety and effectiveness of Cala TAPS™ therapy to aid in the symptomatic relief of hand tremors.
Cala One therapy receives de novo clearance by the FDA for temporary relief of hand tremors in adults with ET.
Cala completes the PROSPECT study: Prospective Study for Symptomatic Relief of Essential Tremor with Cala Therapy, the largest noninvasive therapeutic clinical research study ever conducted for treatment of essential tremor. The study demonstrated that Cala TAPS therapy, repeatedly used at home over three months, resulted in safe and effective hand tremor reduction and improved quality-of-life for adults with ET.
Cala Health receives FDA Breakthrough Device Designation for Cala TAPS therapy to treat action tremors in Parkinson’s disease.
CMS creates unique HCPCS codes for Cala TAPS therapy, facilitating a path to healthcare claims processing for TAPS therapy.
Publication of the first retrospective, long-term real world evidence of TAPS in the Journal of Tremor and Other Hyperkinetic Movements.
Cala launches the next generation device to deliver TAPS therapy, the Cala kIQ® system.
Cala receives positive Medicare Local Coverage Determination for TAPS therapy for essential tremor (ET) from the Centers for Medicare & Medicaid Services (CMS): External Upper Limb Tremor Stimulator Therapy L39591.
Cala launches the next generation of TAPS therapy, the Cala kIQ® Plus, with multiple therapy modes and adaptive calibration.
Cala Health is powering the age of bioelectronic medicine and propelling a paradigm shift in healthcare. The combination of our unique approach and the multitude of applications of TAPS provide opportunities to make a difference in the lives of people living with many different diseases, both now and in the future.
NeuroVoices: Kate Rosenbluth, PhD, on Expanding Noninvasive Treatment for Essential Tremor With Cala kIQ Plus
See yourself working here?
Join our mission to set a new standard of care for chronic disease.